MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control
Authors' conclusion
Our study highlights the effectiveness and safety of MiniMed 780G in the pediatric population.
Study context
- Population
- Children and adolescents aged 7–18 years with T1D in their first 6 months of MiniMed 780G use; 54.1% female
- Participants
- 111 children
- Outcome
- Glycemic outcomes with MiniMed 780G
- Follow-up
- 3 and 6 months
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
Achievement of clinical targets (aggregated data) · entire study period
- Time in range (TIR) >70% achieved
- 72.1%
- Coefficient of variation (CV) <36% achieved
- 74.8%
- Glucose management indicator (GMI) <7% achieved
- 68.5%
- Time below range (TBR) <4% achieved
- 74.8%
- All clinical targets achieved concomitantly
- 44 (39.6%)
Observational data: associations, not effects.
Secondary outcomes
Predictors of optimal glucose control (TIR >70%, CV <36%, GMI <7%, TBR <4%)
- Older age, briefer duration of disease and shorter active insulin time were significant predictors on regression analysis
- Achieving glycemic targets observed in the subgroup with lower mean HbA1c in the year before MiniMed 780G use
Original publication
MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control. Diabetes Technol Ther. Published 3 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →